Charles B. Eaton MD, MS
Eaton MD C.; Adding candesartan-HCTZ to rosuvastatin increased adverse events but not benefits in patients at intermediate CV risk. Ann Intern Med. 2016;165:JC8. doi: 10.7326/ACPJC-2016-165-2-008
Download citation file:
Published: Ann Intern Med. 2016;165(2):JC8.
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Cardiology, Nephrology, Dyslipidemia, Hypertension, Coronary Risk Factors.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only